drug
repurpos
strategi
consist
find
new
indic
alreadi
known
market
drug
use
variou
clinic
set
highli
character
compound
despit
fail
drug
recent
emerg
altern
approach
rapid
identif
develop
new
pharmaceut
variou
rare
complex
diseas
lack
effect
drug
treatment
success
rate
drug
repurpos
approach
account
approxim
new
fda
approv
drug
vaccin
recent
year
review
focus
statu
drug
repurpos
approach
variou
diseas
includ
skin
diseas
infect
inflammatori
cancer
neurodegen
diseas
effort
made
provid
structur
featur
mode
action
drug
keyword
cancer
drug
reposit
drug
reprofil
recycl
drug
drug
discoveri
inflamm
neurodegen
diseas
skin
diseas
sinc
clinic
preclin
studi
repurpos
candid
alreadi
document
origin
indic
thu
reduc
time
cost
need
reach
market
risk
intrins
research
develop
program
moreov
risk
clinic
failur
also
low
ad
advantag
approach
give
possibl
widen
market
prolong
applic
patent
life
drug
mainli
two
way
proceed
drugreposit
approach
experiment
strategi
comput
strategi
experiment
repurpos
strategi
includ
bind
assay
phenotyp
screen
method
find
bind
interact
drug
molecul
assay
compon
identifi
lead
compound
vide
rang
compound
librari
respect
comput
approach
categor
targetmechan
base
knowledgebas
pathwayand
networkbas
approach
approach
proven
econom
discov
novel
therapeut
ligand
notabl
comput
method
augment
drug
discoveri
process
effect
util
cheminformat
bioinformat
network
biolog
system
biolog
specif
method
exploit
known
target
drug
diseas
biomark
pathway
establish
novel
method
acceler
plan
crucial
clinic
trial
perspect
focus
statu
drug
repurpos
approach
variou
diseas
includ
skin
diseas
infect
inflammatori
cancer
neurodegen
diseas
effort
made
provid
structur
featur
mode
action
drug
exclus
small
molecul
peptidomimet
macrocycl
compound
antibodi
vaccin
biolog
drug
discuss
drug
reposit
skin
whiten
activ
melanin
collect
natur
pigment
primarili
determin
skin
hair
hair
color
human
melanocyt
found
basal
layer
epidermi
produc
melanin
process
call
melanogenesi
upon
skin
exposur
ultraviolet
uv
radiat
although
sir
jame
whyte
black
winner
nobel
prize
medicin
report
food
drug
administr
fda
approv
agent
human
protein
come
classif
enzym
transport
g
proteincoupl
receptor
gpcr
cluster
differenti
cd
marker
voltageg
ion
channel
nuclear
receptor
fact
typic
de
novo
drug
discoveri
program
take
year
identif
lead
molecul
market
drug
probabl
success
rate
less
five
year
number
new
drug
approv
fda
around
per
year
although
billion
us
dollar
spent
variou
pharma
industri
research
develop
success
rate
less
new
drug
discoveri
develop
far
away
address
unmet
clinic
need
diseas
treatment
effect
therapeut
complex
diseas
like
alzheim
diseas
ad
parkinson
diseas
pd
cardiovascular
diseas
neglect
diseas
still
lack
outcom
strongli
suggest
new
strategi
approach
technolog
need
acceler
drug
discoveri
advanc
success
rate
drug
develop
drug
repurpos
strategi
consist
find
new
indic
alreadi
known
market
drug
use
variou
clinic
set
highli
character
compound
despit
fail
drug
drug
discoveri
program
faster
safer
develop
medic
diseasesdisord
potenti
treatment
avail
recent
year
success
rate
drug
repurpos
approach
account
approxim
newli
fda
approv
drug
vaccin
one
main
reason
pharmaceut
compani
show
interest
drug
repurpos
approach
approach
requir
initi
six
year
typic
need
develop
new
drug
addit
mani
phase
de
novo
drug
discoveri
develop
bypass
melanin
protect
human
skin
radiat
continu
irradi
result
risk
skin
damag
malign
melanoma
cancer
melanocyt
besid
abnorm
product
melanin
lead
seriou
dermatolog
disord
includ
melasma
freckl
age
spot
postinflammatori
melanoderma
melanogenesi
process
synthesi
melanin
complex
enzymat
biochem
catalyz
reaction
tyrosinas
play
ratelimit
step
hydroxyl
ltyrosin
ldopa
follow
oxid
ldopa
ldopaquinon
serv
substrat
product
melanin
therefor
target
tyrosinas
recogn
potenti
approach
control
abnorm
product
melanin
tyrosinas
also
import
target
food
industri
inhibit
tyrosinas
prevent
enzymat
brown
fruit
veget
besid
essenti
wound
heal
process
immun
respons
mani
plant
spong
invertebr
abnorm
activ
tyrosinas
link
neurodegen
disord
includ
parkinson
huntington
diseas
thiourea
analog
tyrosinas
inhibitor
broadli
classifi
two
categori
polyphenol
mostli
natur
product
arbutin
hydroquinon
kojic
acid
b
thiourea
deriv
sinc
phenylthiourea
ptu
well
known
tyrosinas
inhibitor
mani
research
group
includ
extens
studi
structureact
relationship
ptu
tyrosinas
inhibitor
choi
et
al
screen
fda
approv
drug
librari
close
structur
similar
ptu
see
figur
exampl
ethionamid
secondlin
antituberculosi
drug
use
treatment
multidrug
resist
tuberculosi
share
chemic
similar
led
discoveri
new
mushroom
tyrosinas
inhibitor
ic
valu
commerci
avail
analog
includ
prothionamid
thioisonicotinamid
thiobenzamid
identifi
potent
tyrosinas
inhibitor
particular
compound
strong
inhibitori
activ
molecul
suggest
pyridin
ring
compound
replac
aromat
moieti
includ
benzen
ring
howev
poor
inhibitori
activ
isoniazid
firstlin
antituberculosi
drug
suggest
carbothiomid
group
crucial
tyrosinas
inhibitori
activ
moreov
compar
inhibitori
activ
drug
impli
addit
aliphat
tail
requir
inhibit
tyrosinas
inhibitori
kinet
studi
suggest
drug
analog
revers
noncompetit
cellular
assay
drug
markedli
decreas
melanin
content
cell
valu
respect
without
induc
cytotox
concentr
studi
suggest
drug
strong
inhibit
mammalian
tyrosinas
howev
inhibit
exhibit
drug
analog
weaker
obtain
ptu
observ
enzym
melanin
content
assay
research
group
continu
search
molecul
clinic
usag
contain
thiourea
moieti
result
could
retriev
thiourea
contain
drug
thioacetazon
ambazon
methimazol
carbimazol
thiouracil
methylthiouracil
propylthiouracil
thioacetazon
also
call
thiacetazon
antituberculosi
drug
ambazon
oral
antisept
drug
use
europ
five
molecul
antithyroid
drug
drug
except
exhibit
remark
inhibitori
activ
mushroom
tyrosinas
see
ic
valu
figur
although
compar
weaker
kinet
studi
tyrosinas
inhibit
assign
thioureacontain
drug
noncompetit
inhibitor
cellular
assay
use
cell
drug
among
thiourea
significantli
decreas
melanin
content
without
induc
cytotox
enzymat
studi
cell
extract
cell
confirm
thioureacontain
drug
affect
function
mammalian
tyrosinas
extend
studi
group
reposit
thiopurin
drug
tyrosinas
inhibitor
thioguanin
drug
use
treatment
leukemia
one
essenti
medicin
requir
basic
health
system
recommend
world
health
organ
inhibit
tyrosinas
activ
k
valu
addit
two
thiopurin
drug
mercaptopurin
azathioprin
discov
tyrosinas
inhibitor
among
drug
show
stronger
k
valu
k
drug
azathioprin
exhibit
poor
tyrosinas
inhibit
result
suggest
sulfur
atom
possibl
play
import
role
interact
tyrosinas
interestingli
thioinosin
metabol
product
mercaptopurin
attach
sugar
moieti
exhibit
excel
tyrosinas
inhibitori
activ
k
valu
kinet
studi
classifi
drug
competit
inhibitor
cellular
assay
drug
inhibit
melanin
content
without
cytotox
particular
drug
concentr
remark
reduc
melanin
content
without
appar
cytotox
thiopurin
drug
dock
four
differ
crystal
structur
complex
inhibitor
tropolon
kojic
acid
hydroquinon
ptu
figur
molecular
also
predict
intramolecular
hydrophil
contact
residu
disappear
mercaptopurin
figur
wherea
thioguanin
figur
thioinosin
possess
contact
within
thioinosin
repres
figur
adopt
public
choi
j
et
al
drug
reposit
cancer
therapi
cancer
one
lead
caus
death
worldwid
pharmaceut
compani
invest
billion
dollar
develop
new
anticanc
drug
drug
discoveri
develop
process
cancer
treatment
take
averag
year
cost
approxim
billion
howev
drug
enter
clinic
trial
approv
prolong
durat
drug
develop
enorm
cost
pre
clinic
trial
approv
emphas
need
drug
repurpos
approach
see
figur
drug
repurpos
cancer
therapi
aspirin
also
known
acetylsalicyl
acid
one
nonsteroid
antiinflammatori
drug
nsaid
wide
use
analges
antipyret
prevent
heart
attack
stroke
first
time
gasic
cowork
report
possibl
role
aspirin
cancer
therapi
discov
antiplatelet
activ
tumorbear
mice
associ
reduct
lung
metastasi
recent
studi
also
indic
daili
intak
drug
mg
produc
signific
benefici
effect
gastrointestin
esophag
pancreat
brain
prostat
lung
cancer
mode
action
aspirin
report
modul
numer
molecul
associ
tumorigenesi
process
preclin
studi
reveal
anticanc
activ
drug
attribut
inhibit
cyclooxygenas
cox
enzym
promot
carcinogenesi
synthesi
prostaglandin
pg
includ
besid
drug
report
inhibit
activ
transcript
factor
critic
regul
express
gene
involv
apoptosi
studi
report
li
ling
et
al
compound
inhibit
prolifer
promot
apoptosi
cancer
cell
also
delay
overcam
acquir
resist
target
therapi
underli
mechan
could
attribut
enhanc
cancer
stem
activ
nfkb
signal
acquir
resist
tumor
suppress
aspirin
render
resist
tumor
sensit
aspirin
parent
sensit
cell
term
prolifer
apoptosi
cancer
stem
contrari
aspirin
effect
normal
lung
mammari
epitheli
cell
prolifer
concentr
use
lung
breast
cancer
cell
henc
aspirin
could
potenti
candid
combin
therapi
lung
breast
cancer
studi
suggest
anticanc
properti
aspirin
link
pathway
rasrafmekerk
signal
cascad
numer
studi
suggest
potent
anticanc
activ
drug
overal
benefit
limit
associ
seriou
side
effect
includ
gastrointestin
renal
toxic
therefor
clear
recommend
take
populationwid
use
hand
primari
cancer
prevent
tool
mani
report
reveal
use
would
greater
benefit
popul
age
thu
us
prevent
servic
task
forc
recommend
statement
uspstf
recommend
daili
intak
patient
year
increas
risk
cardiovascular
diseas
colorect
cancer
celecoxib
belong
famili
nsaid
use
treat
pain
inflamm
associ
rheumatoid
arthriti
ra
osteoarthr
oa
fda
approv
celecoxib
highli
select
revers
inhibitor
wellknown
inflammatori
cancer
target
inhibitori
activ
antitumor
activ
drug
extens
studi
shown
chemoprevent
activ
variou
cancer
type
celecoxib
target
glycogen
synthas
kinas
gsk
viru
oncogen
cellular
homolog
akt
b
cell
lymphoma
bcl
famili
peopl
famili
adenomat
polyposi
fap
daili
dosag
drug
mg
significantli
reduc
risk
colorect
adenoma
fda
approv
compound
reduc
colon
rectal
polyp
peopl
famili
adenomat
polyposi
howev
associ
drawback
includ
gastrointestin
renal
cardiotox
effect
ibuprofen
nsaid
primarili
use
treat
fever
pain
inflamm
molecular
level
ibuprofen
inhibit
cox
convert
arachidon
acid
prostaglandin
howev
select
toward
isoform
cox
drug
market
treatment
rheumatoid
arthriti
unit
kingdom
unit
state
well
anticanc
activ
drug
investig
variou
cancer
cell
type
ibuprofen
shown
inhibit
growth
prostat
cancer
cell
adenocarcinoma
gastric
cell
drug
show
antitumor
effect
mediat
antiangiogenesi
induct
apoptosi
reduct
cell
prolifer
administr
drug
induc
apoptosi
metastat
melanoma
cell
line
ibuprofen
also
report
increas
chemosensit
cisplatin
decreas
level
heat
shock
protein
lung
cancer
cell
import
part
cell
machineri
protein
fold
function
associ
resist
apoptosi
therefor
block
ibuprofen
increas
apoptosi
increas
sensit
cisplatin
thalidomid
immunomodulatori
drug
origin
develop
sedativehypnot
treatment
nausea
pregnanc
howev
withdrawn
due
teratogen
effect
drug
demonstr
whether
could
use
treat
patient
refractori
myeloma
antiangiogen
activ
success
clinic
evalu
fda
approv
drug
treat
multipl
myeloma
addit
molecul
also
show
efficaci
sever
malign
includ
acut
myeloid
leukemia
myelodysplasia
myelodysplast
syndrom
mechanist
thalidomid
bind
cereblon
form
ubiquitin
ligas
complex
result
rapid
ubiquitin
proteasom
degrad
transcript
factor
ikaro
aiolo
two
transcript
factor
transcript
regul
b
cell
develop
metformin
oral
avail
firstlin
drug
wide
use
treatment
type
diabet
molecular
mechan
metformin
involv
activ
adenosin
monophosph
amp
induc
protein
kinas
ampk
key
enzym
regul
cellular
metabol
rapamycin
mtor
gene
involv
surviv
cancer
cell
neg
regul
ampk
metformin
also
abl
reduc
signal
mtor
inhibit
ragmedi
activ
mtor
gener
diabet
patient
increas
risk
sever
cancer
type
especi
diabet
women
risk
develop
breast
cancer
sever
studi
suggest
anticanc
properti
drug
drug
dose
mgday
shown
reduc
risk
cancer
well
daili
dose
reduc
incid
gastrolog
cancer
patient
diabet
sever
review
metaanalysi
suggest
take
drug
associ
reduc
risk
cancer
mortal
patient
diabet
recent
metaanalysi
sever
antidiabet
drug
found
patient
use
drug
overal
reduc
risk
cancer
decreas
mortal
rate
respect
wherea
use
insulin
associ
increas
risk
cancer
mortal
recent
phase
clinic
trial
studi
use
occurr
colorect
adenoma
biomark
cancer
primari
endpoint
year
intervent
reveal
metformin
reduc
occurr
number
adenomaspolyp
patient
low
dosag
level
methotrex
competit
inhibitor
dihydrofol
reductas
dhfr
critic
enzym
involv
synthesi
dna
rna
thymidyl
protein
hydrofol
inhibitori
activ
drug
respons
antileukemia
activ
besid
drug
effect
wide
rang
malign
includ
breast
head
neck
leukemia
lymphoma
lung
osteosarcoma
bladder
trophoblast
neoplasm
fda
approv
compound
treatment
osteosarcoma
breast
cancer
acut
lymphoblast
leukemia
hodgkin
lymphoma
sever
report
suggest
antitumor
activ
methotrex
also
due
abil
target
inflammatori
pathway
instanc
methotrex
report
suppress
releas
adenosin
cancer
cell
rapamycin
also
known
sirolimu
origin
develop
antifung
agent
howev
drug
withdrawn
due
potent
immunosuppress
antitumor
activ
mechanist
drug
inhibit
cell
b
cell
decreas
sensit
inhibit
mtor
highli
upregul
mani
tumor
cell
year
fda
approv
rapamycin
prevent
allograft
reject
drug
investig
anticanc
properti
recent
studi
drug
report
reduc
coloni
format
leukemia
progenitor
cell
patient
acut
myeloid
leukemia
addit
drug
also
show
efficaci
patient
imatinibresist
chronic
myelogen
leukemia
suppress
vascular
endotheli
growth
factor
vegf
mrna
level
leukemia
cell
mild
side
effect
diclofenac
acet
acid
deriv
nsaid
class
use
treat
pain
inflammatori
diseas
gout
mode
action
believ
suppress
phase
ii
clinic
trial
investig
combin
calcitriol
recurr
prostat
cancer
result
show
combin
well
toler
statin
famili
drug
lipidlow
agent
inhibit
ratelimit
hmgcoa
reductas
cholesterol
biosynthesi
pathway
statin
commonli
prescrib
reduc
cholesterol
synthesi
patient
high
risk
cardiovascular
diseas
addit
statin
inhibit
mevalon
pathway
provid
mevalon
farnesyl
geranyl
pyrophosph
molecul
import
cell
cycl
progress
cell
prolifer
therefor
statin
repres
promis
candid
cancer
therapeut
chronic
myeloid
leukemia
cell
simvastatin
natur
statin
includ
mevastatin
lovastatin
pravastatin
display
tnfinduc
apoptosi
downregul
mediat
antiapoptot
gene
product
anticanc
activ
statin
also
investig
anim
studi
statin
effect
reduc
incid
growth
tumor
sever
observ
studi
metaanalysi
support
posit
correl
use
statin
chemoprevent
effect
human
metaanalys
reveal
use
statin
reduc
risk
patient
gastric
cancer
well
esophag
hepatocarcinoma
cancer
type
casecontrol
studi
drug
dosag
mgday
year
significantli
reduc
incid
colorect
cancer
depakin
valproic
acid
vpa
shortchain
free
fatti
acid
mainli
use
treat
epilepsi
bipolar
disord
migrain
anticonvuls
activ
attribut
blockad
voltageg
sodium
channel
increas
level
gammaaminobutyr
acid
gaba
brain
anticanc
activ
drug
first
establish
leukemia
cell
drug
shown
inhibit
histon
deacetylas
hdac
depakin
also
found
suppress
product
cytokin
modul
inflammatori
signal
cascad
human
leukemia
human
glioma
cell
drug
abl
suppress
product
prostat
cancer
cell
drug
suppress
inhibit
activ
clinic
trial
drug
advanc
phase
ii
sarcoma
thyroid
cancer
acut
myelogen
leukemia
b
cell
lymphoma
breast
cancer
melanoma
nonsmal
smallcel
lung
cancer
prostat
cancer
recurr
glioblastoma
relapsedrefractori
leukemia
wwwclinicaltrialsgov
recent
abdullah
et
al
shown
pitavastatin
antagon
catalyt
activ
treatment
acut
myeloid
leukemia
aml
significantli
chang
last
decad
new
therapeut
approach
need
achiev
prolong
surviv
rate
bromocriptin
ergolin
deriv
dopamin
agonist
use
treatment
parkinson
diseas
acromegali
hyperprolactinemia
galactorrhoea
recent
reposit
diabet
mellitu
repurpos
strategi
handl
laracastillo
carmen
et
al
shown
bromocriptin
potent
antileukemia
drug
mainli
target
leukemia
stem
cell
typic
drugdiscoveri
program
develop
new
potent
antivir
agent
obtain
approv
clinic
use
take
year
effect
vaccin
drug
approv
treat
infect
although
mani
pre
clinic
develop
henc
drug
use
treatment
diseas
disord
may
inhibit
replic
coronavirus
cov
might
use
attempt
save
life
sever
affect
patient
search
potenti
antivir
agent
merscov
de
wild
et
al
identifi
four
drug
chloroquin
chlorpromazin
loperamid
lopinavir
screen
fda
approv
drug
librari
figur
abl
inhibit
replic
merscov
low
micromolar
rang
addit
four
drug
inhibit
sarscov
well
human
coronaviru
hcov
suggest
could
use
broadspectr
antivir
activ
mode
action
compound
yield
seri
hit
compound
primarili
categor
anticanc
antipsychot
antidepress
antipsychot
pathway
interestingli
cotreat
drug
gemcitabin
deoxycytidin
analog
commonli
use
treatment
cancer
show
synergist
antivir
effect
minim
cytotox
effect
support
hypothesi
use
combin
therapi
treat
cov
diseas
dengu
fever
lifethreaten
diseas
caus
four
antigen
distinct
dengu
viru
serotyp
becam
global
burden
caus
approxim
million
infect
year
around
peopl
die
even
though
vaccin
dengu
avail
longterm
protect
action
serotyp
dengu
viru
remain
yet
determin
besid
current
clinic
approv
antivir
therapi
avail
combat
viru
among
mani
approach
appli
identifi
novel
drug
dengu
fever
drug
repurpos
gain
much
attent
scientif
commun
sever
antivir
antimalari
antidiabet
antihistamin
anticanc
antipsychot
antiparasit
anticholesterem
drug
repurpos
combat
dengu
viru
infect
recent
public
botta
et
al
discuss
class
drug
reposit
detail
identifi
novel
potent
drug
candid
approv
drug
lovastatin
chloroquin
prednisolon
balapiravir
celgosivir
investig
proofoff
concept
clinic
trial
dengu
viral
infect
figur
although
result
show
safe
patient
acut
dengu
drug
fail
meet
priordefin
trial
endpoint
besid
two
clinic
trial
conduct
thailand
singapor
involv
ivermectin
ketotifen
preliminari
result
quit
promis
phase
studi
drug
suggest
reduct
serum
level
bodi
temperatur
recent
malakar
et
al
screen
variou
class
fda
approv
drug
includ
aminolevulin
acid
azela
acid
mitoxantron
hydrochlorid
quinin
sulfat
test
abil
inhibit
dengu
viru
denv
replic
figur
repres
exampl
drug
repurpos
dengu
infect
aminolevulin
acid
endogen
nonproteinogen
amino
acid
azela
acid
use
treat
skin
diseas
mitoxantron
hydrochlorid
anthracenedion
antineoplast
agent
use
treatment
leukemia
quinin
sulfat
natur
compound
extract
cinchona
bark
commerci
avail
tablet
brand
name
qualaquin
wide
use
treat
chloroquineresist
plasmodium
falciparum
abil
reduc
viral
replic
also
demonstr
herp
simplex
viru
hsv
influenza
viru
among
four
drug
investig
drug
found
effect
inhibit
replic
denv
compar
untreat
control
other
show
moder
reduct
impress
drug
abl
reduc
viru
replic
four
serotyp
denv
three
differ
cell
line
human
origin
molecular
level
inhibit
denv
replic
reduc
viral
protein
rna
synthesi
dosedepend
manner
moreov
drug
enhanc
express
gene
relat
innat
immun
respons
find
suggest
efficaci
drug
stimul
antivir
gene
led
reduc
denv
replic
anoth
set
prescrib
drug
candid
test
bloodstag
p
falciparum
cultur
figur
liverstag
p
berghei
show
promis
antimalari
activ
ic
valu
rang
nm
drug
raloxifen
hydrochlorid
salirasib
figur
promis
cancer
drug
candid
inhibit
isoprenylcystein
carboxyl
methyltransferas
icmt
valid
target
cancer
drug
develop
recent
salirasib
analog
repupos
pontenti
antimalari
activ
gener
triazol
derivart
known
potent
antimalari
activ
compound
investig
vitro
toxic
p
falciparum
asexu
stage
vero
cell
antiplasmodi
activ
assay
perform
use
simpl
highsensit
methodolog
base
nanoluciferas
nluc
transfect
p
falciparum
parasit
result
show
analog
activ
low
micromolar
concentr
alzheim
common
type
dementia
affect
around
peopl
age
age
third
age
year
approxim
million
peopl
worldwid
ad
dementia
result
million
death
estim
million
peopl
dementia
worldwid
therefor
ad
repres
major
rise
public
health
concern
urgent
need
develop
therapi
effect
ad
refer
devast
condit
lead
progress
cognit
declin
function
impair
loss
independ
accumul
peptid
enrich
neurit
plaqu
neurofibrillari
tangl
synapt
neuron
dysfunct
well
loss
combin
associ
neurochem
chang
brain
crucial
patholog
event
ad
recent
work
suggest
higher
level
total
tau
may
potenti
toxic
effect
factor
inflammatori
process
mitochondri
function
also
like
import
role
three
acetylcholinesteras
inhibitor
includ
donepezil
rivastigmin
costeffect
exampl
acetylcholinesteras
inhibitor
improv
cognit
pretreat
perform
month
avail
drug
substanti
advanc
treatment
patient
ad
persist
need
build
increas
understand
diseas
pathogenesi
develop
effect
symptomat
treatment
diseasemodifi
therapi
drug
md
simul
result
expos
five
drug
risperidon
domperidon
verapamil
tamsulosin
cinitaprid
show
better
profil
respect
rmsd
rmsf
sasa
rg
evalu
graph
steadi
stabl
behavior
dock
complex
invitro
ach
inhibit
assay
bestscreen
drug
perform
spectrophotometr
method
use
acetylthiocholin
iodid
substrat
enzym
inhibit
kinet
mechan
drug
show
cinitaprid
good
therapeut
potenti
respect
standard
drug
well
known
cintaprid
gastroprokinet
agent
antiulc
agent
benzamid
class
agonist
receptor
antagonist
receptor
base
aforement
result
justifi
cinitaprid
better
reposit
profil
may
use
treatment
ad
clinic
assess
effort
develop
effect
therapi
far
unsuccess
sever
highprofil
clinic
trial
fail
demonstr
benefit
reason
probabl
multifactori
major
put
diseasemodifi
therapi
evalu
target
amyloid
patholog
lack
breadth
treatment
approach
critic
comment
argu
sophist
knowledg
diseas
pathway
need
develop
effect
candid
therapi
exampl
phase
ii
trial
tarenflurbil
figur
provid
suggest
benefit
posthoc
subgroup
analysi
put
mechan
action
via
modul
relat
impact
amyloid
patholog
never
confirm
patient
ad
subsequ
phase
iii
trial
neg
outcom
although
result
phase
ii
trial
dimebon
much
favor
analog
figur
seem
signific
benefit
seen
treatment
group
driven
largerthanexpect
deterior
group
receiv
placebo
treatment
mechan
action
well
character
central
nervou
system
cn
angiotensin
ii
mediat
key
process
includ
releas
inflammatori
mediat
vasoconstrict
mitochondri
dysfunct
inhibit
acetylcholin
releas
central
synaps
propos
relev
ad
potenti
target
therapeut
intervent
base
background
propos
angiotensin
receptor
blocker
arb
may
confer
symptomat
benefit
cognit
largescal
screen
antihypertens
drug
want
et
al
identifi
arb
valsartan
figur
compound
abl
reduc
accumul
cultur
neuron
inhibit
aggreg
vitro
group
demonstr
reduc
plaqu
burden
well
improv
learn
memori
cognit
test
includ
morri
water
maze
task
follow
month
treatment
valsartan
transgen
mice
result
greatest
benefit
seen
dose
mg
kgday
equival
time
maximum
recommend
dose
treat
patient
hypertens
use
anoth
arb
olmesartan
figur
takeda
et
al
demonstr
daili
treatment
young
mice
one
month
improv
cerebr
blood
flow
without
affect
level
mous
model
fragment
inject
intracrani
gener
deficit
pretreat
telmisartan
figur
increas
cerebr
blood
flow
inhibit
plaqu
deposit
howev
physiolog
relev
model
unclear
perhap
strike
preclin
evid
come
studi
losartan
figur
administ
intranas
mice
dose
much
lower
mediat
hypotens
effect
drug
led
reduct
plaqu
compar
vehicletr
mice
also
reduc
level
proinflammatori
mediat
increas
level
antiinflammatori
mediat
serum
anim
overal
signific
reduct
incid
dementia
patient
take
arb
compar
take
compar
cardiovascular
drug
hazard
ratio
confid
interv
take
angiotensinconvert
enzym
ace
inhibitor
lisinopril
hazard
ratio
confid
interv
although
evid
potenti
arb
ad
conflict
difficult
interpret
view
suffici
indic
potenti
benefit
merit
vivo
work
clarifi
rel
import
differ
mechan
optim
dose
optim
agent
could
lead
proofofconcept
studi
patient
ad
best
evid
vitro
vivo
studi
point
either
drug
prefer
arb
anim
studi
also
highlight
drug
potenti
candid
howev
unfortun
disconnect
vivo
clinic
studi
formal
studi
provid
direct
clinic
evid
far
conduct
promis
candid
calcium
channel
blocker
ccb
dihydropyridin
class
wide
use
treat
hypertens
angina
vasodilatori
activ
smooth
muscl
vasculatur
drug
class
good
bloodbrain
barrier
penetr
induc
cerebr
vasodilat
increas
cerebr
blood
flow
anim
human
vitro
studi
reveal
certain
ccb
reduc
product
oligomer
accumul
rescu
neurotox
improv
cell
surviv
presenc
ccb
also
shown
reduc
glutamateinduc
cell
death
level
intracellular
calcium
abil
ccb
prevent
product
investig
chines
hamster
ovari
cell
cho
pari
et
al
iwasaki
et
al
studi
amlodipin
nilvadipin
figur
identifi
agent
inhibit
product
howev
concentr
studi
severalfold
higher
achiev
therapeut
isradipin
figur
shown
neuroprotect
effect
apoptosi
neuroblastoma
cell
line
protect
effect
drosophila
melanogast
model
neurotox
brainpenetr
mous
model
ad
also
report
differenti
effect
ccb
indic
potenti
benefit
ad
probabl
independ
antihypertens
activ
may
specif
individu
drug
within
class
dihydropyridin
seem
effect
compound
differ
chemic
structur
verapamil
diltiazem
evid
preclin
studi
highlight
nilvadipin
best
therapeut
candid
clinic
evid
regard
potenti
benefit
ccb
nimodipin
figur
patient
clinic
signific
dementia
evid
summar
cochran
review
nimodipin
trial
patient
dementia
review
report
treatment
show
efficaci
improv
cognit
activ
daili
live
dose
mgday
howev
evid
limit
small
size
durat
mostli
week
trial
well
lack
oper
diagnost
criteria
ad
vascular
dementia
tetracyclin
antibiot
wide
use
treat
bacteri
infect
well
toler
older
peopl
treatment
data
pertain
shortterm
period
exposur
studi
relat
ad
predominantli
focus
minocyclin
figur
lipophil
tetracyclin
greater
bloodbrain
barrier
penetr
agent
class
concern
preclin
studi
drug
shown
reduc
aggreg
promot
disassembl
preform
fibril
vitro
variou
group
independ
shown
drug
reduc
level
proinflammatori
mediat
microgli
activ
rang
mous
model
ad
besid
two
three
studi
use
transgen
mous
model
ad
day
treatment
shown
signific
decreas
cerebr
accumul
improv
behavior
outcom
well
one
studi
use
mice
report
reduct
cortic
amyloid
level
follow
month
minocyclin
treatment
chang
tau
patholog
observ
third
studi
report
benefit
concern
amyloid
accumul
behavior
treatment
period
addit
studi
rat
model
diabet
demonstr
reduct
level
associ
improv
behavior
outcom
week
treatment
doxycyclin
second
gener
antibiot
tetracyclin
class
promis
drug
test
mani
clinic
trial
number
differ
patholog
compound
endow
antiamyloidogen
properti
better
cross
bloodbrain
barrier
efficaci
never
test
ad
mice
balducci
claudia
et
al
show
ad
mice
receiv
differ
treatment
regimen
recov
memori
without
plaqu
reduct
acut
treatment
also
suffici
improv
mous
memori
suggest
action
solubl
abo
confirm
aboinduc
mous
model
abomedi
memori
impair
abolish
pretreat
although
abo
induc
memori
impair
glial
activ
assess
antiinflammatori
action
found
abotr
mice
memori
recoveri
associ
lower
neuroinflamm
data
promot
hope
reposit
drug
counteract
crucial
neuropatholog
ad
target
drug
activ
retino
acid
receptor
rar
use
treat
sever
skinrel
condit
acn
psoriasi
retino
acid
also
vital
normal
nerv
function
repair
genom
epidemiolog
evid
suggest
impair
retino
acid
signal
may
contribut
etiolog
ad
chronic
depriv
retino
acid
rat
lead
deposit
vasculatur
dysregul
amyloid
process
cortex
shown
treatment
retinoid
x
receptor
rxr
agonist
bexaroten
figur
approv
treatment
cutan
cell
lymphoma
lead
patholog
behavior
improv
transgen
mous
model
ad
acut
treatment
drug
last
less
day
caus
rapid
reduct
level
plaqu
burden
young
old
mice
chronic
treatment
result
sustain
reduct
insolubl
level
mechanist
drug
result
upregul
compon
highdens
lipoprotein
hdl
pathway
apolipoprotein
e
apo
promot
proteolyt
degrad
potenti
mechan
action
retinoid
may
includ
upregul
enzym
involv
amyloid
clearanc
insulindegrad
enzym
compon
apo
pathway
retinoid
may
also
induc
potenti
benefici
chang
relat
insulin
signal
increas
neurogenesi
promot
neuron
differenti
progenitor
cell
retinoid
also
act
antioxid
regul
sod
inhibit
glutathion
deplet
reduc
mitochondri
damag
well
antiinflammatori
agent
reduc
product
vitro
activ
potenti
import
ad
patholog
therefor
strong
mechanist
rational
potenti
benefit
retinoid
therapi
beyond
amyloid
modul
need
clarifi
impact
treatment
pathway
vivo
studi
overal
studi
literatur
indic
retinoid
strong
potenti
mechanist
plausibl
therapi
ad
owe
effect
app
process
clearanc
insulin
signal
neurogenesi
approv
drug
data
bexaroten
provid
proof
concept
potenti
candid
treatment
alzheim
diseas
note
wherea
acitretin
figur
known
penetr
tissu
includ
brain
may
also
promis
candid
ad
longterm
degen
disord
cn
mainli
affect
motor
system
pd
affect
million
individu
peopl
die
usual
occur
peopl
age
one
percent
affect
addit
classic
motor
symptom
caus
death
dopaminerg
neuron
parkinson
diseas
encompass
wide
rang
nonmotor
symptom
although
novel
diseasemodifi
medic
slow
stop
parkinson
diseas
progress
develop
drug
repurpos
use
exist
drug
pass
numer
toxic
clinic
safeti
test
new
indic
use
identifi
treatment
compound
strategi
reveal
tetracyclin
promis
candid
treatment
parkinson
diseas
tetracyclin
neuroprotect
inhibit
proinflammatori
molecul
product
matrix
metalloproteinas
activ
mitochondri
dysfunct
protein
misfoldingaggreg
microgli
activ
two
commonli
use
semisynthet
secondgener
tetracyclin
deriv
minocyclin
doxycyclin
exhibit
effect
neuroprotect
activ
experiment
model
neurodegen
neuropsychiatr
diseas
substanti
toxic
moreov
novel
synthet
tetracyclin
differ
biolog
properti
due
chemic
tune
avail
review
discuss
multipl
effect
clinic
properti
tetracyclin
potenti
use
parkinson
diseas
treatment
addit
examin
hypothesi
antiinflammatori
activ
tetracyclin
regul
inflammasom
signal
base
excel
safeti
profil
human
use
year
antibiot
propos
repurpos
tetracyclin
multitarget
antibiot
treat
parkinson
diseas
isradipin
ltype
calcium
channel
blocker
dihydropyridin
class
wide
use
treatment
high
blood
pressur
reduc
risk
heart
attack
stroke
drug
came
medic
use
year
epidemiolog
data
support
calcium
channel
blocker
may
potenti
reduc
risk
develop
pd
among
dihydropyridin
drug
attract
much
inhibit
subtyp
channel
like
mediat
risk
pd
moreov
good
brain
bioavail
drug
made
promis
candid
repurpos
studi
shown
drug
dose
repentantli
protect
dopaminerg
neuron
mptp
induc
toxic
revert
dopaminerg
neuron
latent
juvenil
pacemak
mechan
independ
calcium
openlabel
doseescal
studi
assess
safeti
steadypd
drug
control
releas
mgday
patient
earli
pd
suggest
accept
toler
dose
mg
per
day
howev
higher
dose
caus
leg
edema
dizzi
isradipin
mg
highest
dosag
confirm
anoth
steadypdii
random
doubleblind
trial
undertaken
subject
earli
pd
requir
dopaminerg
therapi
result
suggest
common
advers
effect
peripher
edema
occur
patient
receiv
drug
mg
placebocontrol
phase
iii
clinic
studi
assess
efficaci
drug
inosin
figur
purin
nucleosid
use
dietari
supplement
athlet
improv
aerob
perform
shown
neuroprotect
role
elev
level
serum
urat
natur
antioxid
peroxynitrit
scaveng
properti
potenti
benefit
patient
multipl
sclerosi
mani
studi
suggest
individu
increas
level
urat
serum
reduc
risk
develop
pd
well
patient
pd
associ
reduc
rate
diseas
progress
moreov
toxinbas
model
pd
increas
urat
level
confer
protect
dopaminerg
cell
death
stimul
mptp
rotenon
signal
nuclear
factor
like
thought
involv
effect
therefor
given
data
support
neuroprotect
role
urat
inosin
repurpos
pathogenesi
pd
abil
rais
urat
level
drug
serum
demonstr
surepd
random
doubl
blind
placebocontrol
patient
earli
pd
yet
requir
medic
result
show
inosin
rais
mild
urat
level
mgdl
moder
urat
elev
mgdl
month
welltoler
favor
progress
rate
updr
score
amount
point
per
year
total
updr
scale
hand
elev
level
urat
serum
risk
hypertens
coronari
heart
diseas
stroke
long
term
side
effect
potenti
limit
util
older
patient
pd
howev
patient
asian
origin
pd
inosin
elev
urat
level
mgdl
without
side
effect
year
treatment
report
multicent
trial
involv
larg
number
patient
patient
current
underway
intend
elev
urat
level
mgdl
result
studi
expect
year
simvastatin
sinc
statin
also
known
modul
variou
biolog
process
relev
pathogenesi
pd
simvastatin
repurpos
treat
diseas
pretreat
simvastatin
preserv
dopaminerg
cell
motor
behavior
rodent
treat
promot
antioxid
protein
express
via
modul
nmda
receptor
proinflammatori
cytokin
express
similarli
mptp
model
pretreat
simvastatin
suppress
activ
protect
dopaminerg
neuron
improv
motor
function
although
stain
gener
given
encourag
preclin
studi
epidemiolog
data
regard
associ
usag
statin
risk
pd
unclear
moreov
modest
protect
effect
statin
disappear
adjust
cholesterol
level
howev
due
promis
biochem
pharmacolog
properti
simvastatin
current
examin
patient
moderatestag
pd
phase
ii
doubleblind
random
control
multicent
trial
nilotinib
figur
select
cabl
tyrosin
kinas
inhibitor
approv
treatment
imatinibresist
chronic
myelogen
leukemia
cml
accumul
evid
suggest
cabl
activ
link
pathogenesi
pd
synucleinopathi
activ
phosphoryl
cabl
found
high
level
postmortem
studi
patient
pd
also
report
activ
cabl
mice
induc
neurodegener
hippocamp
striatal
brain
area
continu
work
demonstr
cabl
phosphoryl
occur
result
mitochondri
dysfunct
oxid
stress
promot
accumul
effect
autophagi
mechan
promot
phosphoryl
parkin
caus
inhibit
ubiquitin
ligas
activ
induc
mitochondri
dysfunct
dopaminerg
neuron
death
evid
propos
cabl
may
promis
therapeut
target
manag
pd
cn
penetr
nilotinib
abl
inhibitor
favor
fetch
data
pd
relat
studi
inde
preclin
model
pd
drug
shown
cross
bloodbrain
barrier
reduc
cabl
activ
amelior
autophag
clearanc
transgen
lentivir
genetransf
model
importantli
effect
seen
dose
far
lower
mgkgday
use
treat
cml
consid
key
characterist
potenti
drug
repurpos
furthermor
nilotinib
prevent
dopaminerg
cell
loss
motor
impair
induc
mptp
mice
associ
inhibit
parkin
phosphoryl
reduc
accumul
parkin
substrat
pari
thu
hint
anoth
potenti
mechan
action
base
preclin
data
small
openlabel
proofofconcept
studi
recent
conduct
evalu
safeti
toler
nilotinib
patient
pd
dementia
dementia
lewi
bodi
followedup
week
follow
final
assess
week
later
necessari
lowest
choic
dose
clinic
studi
taken
mg
author
report
nilotinib
well
toler
though
one
patient
receiv
mg
diagnos
myocardi
infarct
two
transient
qtc
prolong
also
evid
cn
penetr
nilotinib
csf
plasma
ratio
mg
respect
due
numer
methodolog
limit
find
interpret
caution
due
unwant
offtarget
nonselect
tyrosin
kinas
inhibit
side
effect
nilotinib
dose
use
treat
cml
includ
cardiac
conduct
abnorm
therefor
claim
toler
interpret
caution
inde
effect
efficaci
also
highli
imposs
conclud
besid
also
report
csf
none
marker
use
valid
biomark
pd
also
vari
greatli
patient
track
poorli
diseas
stage
progress
situat
rais
question
optimum
dose
nilotinib
brain
penetr
assess
cardiovascular
effect
patient
parkinson
diseas
pd
neurodegen
disord
greater
preval
incid
describ
men
suggest
protect
effect
sex
hormon
brain
intellectu
properti
relat
issu
hinder
commerci
reposit
molecul
conclus
repurpos
drug
potenti
find
improv
treatment
variou
diseas
drug
list
plenti
drug
repurpos
variou
therapi
drug
discuss
perspect
summar
tabl
compar
previou
use
drug
repurpos
use
opportun
drug
repurpos
divers
lot
still
done
explor
drug
repurpos
drug
reposit
offer
new
strategi
academ
center
research
council
program
notforprofit
organ
well
pharmaceut
biotechnolog
compani
drug
develop
main
advantag
drug
repurpos
establish
safeti
known
candid
compound
compar
develop
novel
therapeut
compound
time
cost
requir
advanc
candid
clinic
trial
substanti
reduc
vitro
vivo
screen
chemic
optim
toxic
studi
bulk
manufactur
formul
develop
alreadi
complet
mani
case
therefor
bypass
moreov
drug
market
mani
year
consequ
side
effect
alreadi
known
safeti
therefor
high
medicin
chemist
repurpos
drug
cancer
reward
job
global
healthcar
system
possibl
step
forward
peopl
get
cheaper
safer
medicin
rather
afford
cancer
therapi
howev
time
minimum
invest
spent
conduct
studi
improv
safeti
success
repurpos
drug
drug
repurpos
also
offer
possibl
develop
multitarget
drug
interact
one
pathwayprotein
time
complex
diseas
neuro
inflammatori
degen
disord
develop
multitarget
drug
emerg
area
treatment
multipl
advantag
synergist
effect
ii
reduc
drugresist
iii
better
complianc
iv
simplifi
pharmacokinet
pharmacodynam
profil
reduc
risk
drugdrug
interact
hand
limit
drug
repurpos
also
consid
involv
technic
challeng
legal
requir
intellectu
properti
right
could
hamper
whole
process
often
hard
overcom
b
seriou
problem
develop
resist
germ
account
consum
drug
varieti
diseas
c
owe
target
select
difficult
identifi
drug
cure
treat
two
differ
diseas
nevertheless
drug
repurpos
part
solut
sink
number
new
diseas
treatment
howev
quit
hard
replac
common
way
identifi
new
drug
candid
furut
approach
could
improv
mani
differ
way
integr
data
reposit
drug
avail
mani
public
platform
pubchem
